par Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE), Amanda;Mocroft, Peter;Reiss, Ole;Kirk, Cristina;Mussini, Enrico;Girardi, Philippe;Morlat, Christoph;Stephan, Stéphane;De Wit, Katja ;Doerholt, Jade;Ghosn, Heiner H.C.;Bucher, Jens D;Lundgren, Geneviève;Chêne, José María;Miró, Hansjakob;Furrer,
Référence Clinical infectious diseases, 51, 5, page (611-619)
Publication Publié, 2010-09
Référence Clinical infectious diseases, 51, 5, page (611-619)
Publication Publié, 2010-09
Article révisé par les pairs
Résumé : | Current guidelines suggest that primary prophylaxis for Pneumocystis jiroveci pneumonia (PcP) can be safely stopped in human immunodeficiency virus (HIV)-infected patients who are receiving combined antiretroviral therapy (cART) and who have a CD4 cell count >200 cells/microL. There are few data regarding the incidence of PcP or safety of stopping prophylaxis in virologically suppressed patients with CD4 cell counts of 101-200 cells/microL. |